Pituitary & hypothalamus

Comparative analysis of intraoperative and imaging features of invasive growth in pituitary adenomas

Eur J EndocrinolPublished Retrospective cohort study

Authors' conclusion

Both intraoperative and radiographic signs of invasive growth are high-risk lesions for incomplete extent of resection and occur more frequently in older patients. A particularly high prevalence of invasion can be found in the SGCA and SGSA types. Cavernous sinus invasion is also more common in gonadotroph adenomas. Usage of the Knosp classification is a valuable preoperative estimation tool.

Study context

Population
Surgically treated pituitary adenomas, October 2004–April 2018
Participants
764 pituitary adenomas (PAs)
Exposure
Intraoperative vs magnetic resonance imaging (MRI) assessment of invasive growth
Outcome
Invasive growth
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Invasive features on MRI (Knosp grades 3A-4)

24.4%

186/764

Intraoperative invasion

42.4%

324/764

Observational data: associations, not effects.

Further findings

Extent of resection

Complete resection
80.0%
Subtotal resection
20.1%

Factors associated with intraoperative invasion (multivariate)

Sparsely granulated corticotroph adenoma (SGCA)
P = 0.0026
Sparsely granulated somatotroph adenoma (sparsely granulated somatotroph (SGSA))
P = 0.0103
Age
P = 0.0287

Factors correlated with radiographic invasion (Knosp grades 3A-4)

Age
P = 0.0098
SGCAs
P = 0.0005
SGSAs
P = 0.0351
Gonadotroph adenomas
P = 0.0478

Invasion (both criteria) and subtotal resection

Both criteria of invasion correlated with subtotal resection
P = 0.0001, respectively

Original publication

Comparative analysis of intraoperative and imaging features of invasive growth in pituitary adenomas. Eur J Endocrinol. Published 27 May 2024. doi:10.1093/ejendo/lvae059

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.